What is the current valuation of the neuropsychiatric disorders-treatment market in South Korea?

The market was valued at $3630.0 Million in 2024. Read More

What is the projected market valuation for 2035?

The market is expected to reach $10550.0 Million by 2035. Read More

What is the expected CAGR for the South Korea neuropsychiatric disorders-treatment market during 2025 - 2035?

The expected CAGR is 10.19% during the forecast period. Read More

What were the valuations for the Neurotic Disorders segment in 2024?

The Neurotic Disorders segment was valued at $1080.0 Million in 2024. Read More

What is the projected valuation for the Drug Treatment segment by 2035?

The Drug Treatment segment is projected to reach $4200.0 Million by 2035. Read More

Who are the key players in the South Korea neuropsychiatric disorders-treatment market?

Key players include Johnson & Johnson, Pfizer, Eli Lilly and Company, and AstraZeneca. Read More

What is the valuation of the Hospitals segment in 2024?

The Hospitals segment was valued at $1450.0 Million in 2024. Read More

What is the expected growth for the Others segment in the Treatment category by 2035?

The Others segment in the Treatment category is expected to grow to $5300.0 Million by 2035. Read More

How does the valuation of the Psychosis segment compare to the Others segment in 2024?

In 2024, the Psychosis segment was valued at $726.0 Million, whereas the Others segment was valued at $1098.0 Million. Read More

South Korea Neuropsychiatric Disorders Treatment Market

Q: Which segments are included in the neuropsychiatric disorders category?

The segments include Degenerative Diseases, Neurotic Disorders, Psychosis, and Others. Read More

ID: MRFR/HC/43512-HCR

200 Pages

Nidhi Mandole

Last Updated: April 06, 2026

South Korea Neuropsychiatric Disorders Treatment Market Research Report By Type (Degenerative Diseases, Neurotic Disorders, Psychosis, Others), By Application (Shock Treatment, Drug Treatment, Others) and By End User (Hospitals, Clinics, Research Centre’s, Others) - Growth & Industry Forecast 2025 To 2035

South Korea Neuropsychiatric Disorders Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Disorders (USD Million)
  1. 4.1.1 Degenerative Diseases
  2. 4.1.2 Neurotic Disorders
  3. 4.1.3 Psychosis
  4. 4.1.4 Others
2. 4.2 Chemicals and Materials, BY Treatment (USD Million)
  1. 4.2.1 Shock Treatment
  2. 4.2.2 Drug Treatment
  3. 4.2.3 Others
3. 4.3 Chemicals and Materials, BY End User (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Research Centres
  4. 4.3.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Johnson & Johnson (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bristol-Myers Squibb (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Roche (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Otsuka Pharmaceutical (JP)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY DISORDERS
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY END USER
5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
11. 6.11 CHEMICALS AND MATERIALS, BY DISORDERS, 2024 (% SHARE)
12. 6.12 CHEMICALS AND MATERIALS, BY DISORDERS, 2024 TO 2035 (USD Million)
13. 6.13 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISORDERS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea Chemicals and Materials Market Segmentation

Chemicals and Materials By Disorders (USD Million, 2025-2035)

Degenerative Diseases
Neurotic Disorders
Psychosis
Others

Chemicals and Materials By Treatment (USD Million, 2025-2035)

Shock Treatment
Drug Treatment
Others

Chemicals and Materials By End User (USD Million, 2025-2035)

Hospitals
Clinics
Research Centres
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”